Teva Targets $6-7B Innovative Medicine Revenue by 2030, Backs It With $10B Pipeline
TEVA sits 79% above its 52-week low of $24.01.
Summary
Teva laid out long-range targets at its R&D Day: $6-7B in innovative medicine revenue by 2030, innovative gross margins above 75%, mid-single-digit total revenue growth and more than $3.5B of annual free cash flow. Management says it will launch one novel treatment a year for the next five years, backed by a late-stage pipeline it pegs at more than $10B in combined peak sales. Concrete pipeline moves: WELTRUZA jumped straight from Phase 1 to Phase 3, ecopipam went to FDA priority review, and the anti-IL-15 celiac asset hit its Phase 2a primary endpoint with a Phase 2b planned for the second half of 2027. The plan leans on the balance sheet repair already underway — investment-grade rating regained in 2026, net debt leverage targeted at 2.0x by late 2027 — following September's $4.9B equivalent senior notes refinancing. These are multi-year aspirations, not near-term numbers, so the read-through is credibility rather than an earnings revision; the stock is already near its 52-week high after the Q3 beat and guidance raise on November 3. Watch the ecopipam FDA decision and the Phase 2b celiac trial start in the second half of 2027 as the first real tests of the plan.
At the time of this announcement, TEVA was trading at $42.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50B. The 52-week trading range was $24.01 to $43.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.